DRAP decides prices of new generics

ISLAMABAD: A pricing committee of the apex drug regulator in the country has decided on prices for new generics and therapies used to treat chronic and fatal diseases.

The prices will be notified after the cabinet approves them. The Drug Pricing Committee met over two days on December 6 and 7. Representatives from the Ministries of Finance, Health and provincial health departments attended the meeting apart from officers of DRAP.

The committee recommended prices of drugs for new therapies and generics of existing drugs including for patients suffering from Hepatitis-B & C, cancer, lung infections, asthma, Parkinson disease, epilepsy, diabetes, osteoporosis and hypertension.

Published in The Express Tribune, December 8^th, 2017.